Obsessive-Compulsive Disorder Drugs Market: Current Analysis and Forecast (2022-2028)

Obsessive-Compulsive Disorder Drugs Market: Current Analysis and Forecast (2022-2028)

The global obsessive-compulsive disorder drugs market is expected to grow at a significant rate of around 7% during the forecast period. OCD is a long-lasting mental health condition characterized by frequent thoughts or urges and repetitive behaviors or actions that people feel like they continue doing repeatedly. The rising prevalence of obsessive-compulsive disorder and increasing work-related stress are important factors that are responsible for the market growth of OCD drugs. For instance, as per the NIMH, OCD affects 2.5 million adults, or 1.2% of the U.S. population. Furthermore, the rising awareness about the severity of the disease among the population also catalyzes the market dynamics of their OCD drugs.

Abbott, Pfizer Inc., Merck & Co. Inc., Sanofi, Novartis AG, AbbVie Inc., Eli Lilly and Company, AstraZeneca, Meiji Holdings Co., Ltd, Brainsway are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.
 
Insights Presented in the Report
"Amongst drug type, antidepressant category to witness higher CAGR during the forecast period”

Based on the drug type, the market has been categorized into SSRIs, anxiolytic, and antidepressants. The antidepressants category is to witness higher CAGR during the forecast period owing to rapidly increasing cases of mental disorders which were further increased by the lockdowns imposed during the COVID-19 pandemic. For instance, according to the WHO, the burden of mental health problems in India is 2,443 disability-adjusted life years (DALYs) per 10,000 population.
"Amongst distribution channel, the online pharmacies to hold a significant share in the market in 2020”

Based on the distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others. Among these, online pharmacies to hold a significant share in the market in 2020. The rising number of quick commerce platforms and increasing investment in online pharmacies are the important factors that are responsible for the segmental growth in the obsessive-compulsive disorder drugs market.
"North America to hold a significant share in the market”

For a better understanding of the market adoption of the obsessive-compulsive disorder drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. In 2020, North America held a significant share of the global obsessive-compulsive disorder drugs market. This is mainly attributed to the rising number of product launches and the increasing healthcare investments in the region. For instance, in August 2021, Drug firm Alembic Pharmaceuticals received final approval from the US health regulator for Clomipramine Hydrochloride capsules, used for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD).

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.